Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Crb4.0
Cerebrolysin – Forschung
Überwiegend Mechanismus / Beobachtung
31 begutachtete Studien
Was die Evidenz sagt
Überwiegend Mechanismus / Beobachtung
Die meisten Studien zu Cerebrolysin sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2011–2026 mit einer typischen Studiengröße von 238 Teilnehmenden.
Basierend auf 31 Studien · 10 Meta-Analysen · 6 RCTs · 13,450 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Nach Outcome
Stroke & recovery
Überwiegend Mechanismus / Beobachtung19 Studien
Neuroprotection & brain agingPostulierte BDNF/GDNF-ähnliche neurotrophe und neuroprotektive Aktivität; nach Schlaganfall und SHT mit geringen/uneinheitlichen funktionellen Verbesserungen und ohne Mortalitätsnutzen untersucht. · Nicht belegt
Überwiegend Mechanismus / Beobachtung11 Studien
Cognitive functionEin Peptidpräparat, das als Zusatztherapie bei vaskulärer Demenz und Kognition nach Schlaganfall untersucht wurde; die Signale sind schwach und von geringer Qualität, und eine Cochrane-Übersichtsarbeit fand keinen nachgewiesenen Nutzen beim akuten Schlaganfall. · Wochen mit IM/IV-Behandlungszyklen in Studien (Nutzen nicht belegt)
Überwiegend Mechanismus / Beobachtung9 Studien
Safety profile
Überwiegend Mechanismus / Beobachtung7 Studien
Traumatic brain injury
Überwiegend Mechanismus / Beobachtung5 Studien
Aktives Forschungsgebiet
25 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2026
201120182026
1Meta-Analysen=1,601 · large study2020
Moderate-quality evidence indicates that Cerebrolysin probably has little or no beneficial effect on preventing all-cause death in acute ischaemic stroke ... Moderate-quality evidence also indicates a potential increase in non-fatal serious adverse events with Cerebrolysin use.
Cochrane systematic review/meta-analysis of 7 RCTs (1601 participants) in acute ischaemic stroke
No difference in all-cause death (RR 0.90, 95% CI 0.61-1.32; moderate-quality evidence)
Increase in the number of people with non-fatal serious adverse events (RR 2.15, 95% CI 1.01-4.55), more pronounced at the 30 mL / 10-day schedule (RR 2.86, 95% CI 1.23-6.66)
Strict adherence to the OT protocol and extending the duration of OT to 3 months or more significantly enhance treatment outcomes.
Treder-Rochna N, Mańkowska A, Kujawa W, Harciarek M. · Frontiers in human neuroscience (2024)
Conclusions In our assessment, olfactory training alone produces significant improvements in chronic olfactory dysfunctions.
However, a combined therapy approach is essential to achieve more effective outcomes.
Integrating olfactory training with adjuvants like CoUltraPEALut, Cerebrolysin, and oral Vitamin A has demonstrated substantial benefits in enhancing post-COVID-19 olfactory function.
Recent findings from the Efficacy and Safety of Cerebrolysin in the Treatment of Aphasia After Acute Ischemic Stroke study (ESCAS) demonstrate that combined speech therapy and Cerebrolysin use accelerates recovery of speech functions, suggesting its value as an adjunct in stroke rehabilitation.
Bogolepova AN. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026)
Cognitive impairment is a major consequence, with post-stroke aphasia developing in approximately 30% of patients after a first stroke.
Speech therapy is a primary treatment modality.
Neuroplasticity is central to post-stroke recovery, and agents that stimulate neuroplasticity represent a promising therapeutic direction.
We review these studies and discuss the critical need to clearly define the patient population that benefit most from adjunctive Cerebrolysin therapy in AIS.
Ribó M, Staszewski J, Zeiler SR, Michalak S, El Bassiouny A, Gongora-Rivera F, Poljakovic Z, Khasanova DR, Kalinin MN, Chutinet A, Eichel R, Kojder K, Ong M, Bedeković MR, Chang CH, Lee M, Quitasol P, Tsiskaridse A, Bornstein NM. · Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2026)
Beyond its established neurorecovery benefits, recent data indicate that Cerebrolysin also offers protection to the neurovascular unit and the blood-brain barrier.
This paper introduces the CErebrolysin in RECanalization And Perfusion (CERECAP) program, a collaborative initiative of independent academic investigations exploring the favorable trends of Cerebrolysin in reperfusion.
The CERECAP program has generated compelling data demonstrating Cerebrolysin's alignment with current AIS reperfusion therapy concepts, particularly its role in early intervention targeting multiple pathways.
Further large-scale randomized trials are warranted to confirm these effects.
Afridi A, Sajjad F, Arshad A, Shahid I, Fatima NE, Alam U, Hoti RK, Abdullah M, Khan S, GhanimAl-Badri S, Khan S, Bakkar MA, Saeed A, Ali A, Khan LA, Kamil KA. · Brain and behavior (2026)
Interstudy heterogeneity was assessed using I 2 and χ 2 statistics (I 2 > 50% = significant heterogeneity).
Among 71 patients in the Cerebrolysin + MT group and 163 in the MT-alone group, a good functional outcome was achieved in 61 versus 110 patients, respectively (RR: 1.56, 95% CI: 1.25-1.93, p < 0.0001).
There were sustained protective tendencies and a significant decrease in the incidence of symptomatic intracerebral hemorrhage (sICH) (RR: 0.12, 95% CI: 0.03-0.48, p = 0.03). sICH occurred in 4 of 148 patients in the Cerebrolysin group versus 9 of 148 in the control group.
Conclusion The use of Cerebrolysin in a dose of 10 ml to 30 ml during post-stroke rehabilitation leads to an increase in the quantity and quality of restored functions and formed skills, which was shown in a small group of 10 studies.
Shmonin AA, Kashaev IK, Luchinin EA, Bakulin GS. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2026)
Mathematical processing of the arm action test (ARAT) results was performed using the SMD method.
Results The positive effect of potentiating neuroplasticity with Cerebrolysin consists in a significant improvement in daily activity in patients undergoing early comprehensive rehabilitation or physical therapy after a stroke.
Patients statistically significantly restore the functionality of the affected upper limb during long-term rehabilitation initiated in the early subacute period.
In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.
Al-Kuraishy HM, Al-Gareeb AI, Zekry SH, Alruwaili M, Alexiou A, Papadakis M, Batiha GE. · Neuroscience (2025)
Moreover, many studies highlighted that CBL is effective in the improvement of cognitive impairment in patients with neurodegenerative diseases.
However, the underlying neuroprotective effects of CBL against the VD neuropathology were not fully elucidated.
Thus, this review aims to discuss the possible therapeutic efficacy of CBL in the management of VD.
This review summarizes current insights into post-stroke neuroinflammatory mechanisms, with a focus on the dual role of microglial polarization.
Chan TYH, Ma BY, Hung TK, Wong JSY, Lo BWY. · Neurology and therapy (2025)
By bridging mechanistic insights with clinical applications, this review delineates neuroinflammatory modulation as a pivotal frontier for redefining stroke recovery while outlining essential research trajectories to overcome existing barriers.
Systematic search of electronic databases including PubMed, Web of Science, Embase, and Cochrane (1996-2025) was performed, with eligible studies assessed using PRISMA guidelines.
Findings on neuroinflammation, mechanism, or interventions in ischemic stroke were narratively synthesized through thematic analysis.
Although the evidence remains heterogeneous, this review highlights the potential role of neuroprotective agents as adjuncts to reperfusion therapy and identifies promising directions for future clinical trials.
Wesley MJ, Gundala Raja H, Shahid MS, Akbar A, Jeyakumar D, Veluchamy E, Sivakumar M, Tahir F, Jiménez Royg D, Pant R, Rehman A. · Cureus (2025)
Functional outcomes were primarily measured using the modified Rankin Scale (mRS), infarct volume, and safety endpoints such as symptomatic intracranial hemorrhage (sICH).
Among the findings, normobaric hyperoxia showed the most consistent benefit in reducing infarct size and improving functional outcomes, while agents such as nerinetide and edaravone demonstrated mixed results.
Quality assessment using the Cochrane Risk of Bias (RoB) 2.0 tool revealed low to moderate risk of bias across most studies.
In this review, we review the pathophysiology, recent clinical trials, and future directions for acute TBI.
Cook AM, Michas M, Robbins B. · CNS drugs (2025)
New strategies and pharmacotherapy options for neuroprotection continue to be evaluated, including tranexamic acid, progesterone, cerebrolysin, cyclosporin A, citicholine, memantine, and lactate.
Biomarkers of injury that can aid in diagnosis and prognosis have also been elucidated and are incrementally being used in clinical practice.
The spectrum of TBI severity has also gained increasing attention as it relates to mild TBI or concussion, blast injury, and subacute or chronic subdural hematomas.
Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.
Bischoff S, Moyaert M, Clijsters M, Vanderbroek A, Van Gerven L. · Current allergy and asthma reports (2024)
Treatments such as PRP and calcium chelators demonstrated significant improvements on OFS, whereas olfactory training and corticosteroids did not show notable efficacy for COVID-19 associated olfactory dysfunction.
In this systematic review we list clinical data of 36 randomised controlled trials (RCTs) and non-randomised studies published between Jan 1, 2020 and Nov 19, 2023 regarding treatment options for COVID-19 associated olfactory dysfunction.
Nine treatment groups were analysed, including olfactory training, local and systemic corticosteroids, platelet-rich plasma (PRP), calcium chelators, vitamin supplements including palmitoylethanolamide with luteolin, insulin, gabapentin and cerebrolysin.
The Cerebrolysin positive impact was significant in those whose estimated on-admission HT risk was either moderate or high.
Kalinin MN, Khasanova DR. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2024)
Results Heterogeneity of Cerebrolysin treatment effects was moderate (I 2 =36.98-69.3%, H 2 =1.59-3.26) and mild (I 2 =18.33-32.39%, H 2 =1.22-1.48) for symptomatic and any HT, respectively.
HTI≥2: by 3.8%, p =0.120 vs. 14.3%, p <0.001) and any HT (HTI=0 vs.
This review contributes to the ongoing dialogue on optimizing post-stroke recovery and highlights the critical need for evidence-based neuroprotective strategies.
Hassan BD, Dabas MM, Kanemitsu K, Faran N, Abbas T. · Cureus (2024)
Cerebrolysin demonstrated consistent improvement in early neurological function and motor recovery, with a number-needed-to-treat (NNT) of 7.1 for early NIHSS (National Institutes of Health Stroke Scale) score improvements.
Our Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-guided search covered PubMed, Medline, Embase, and the Cochrane Library up to September 2024.
These findings emphasize the mixed efficacy of these neuroprotective interventions and underscore the necessity for personalized treatment protocols and further large-scale, controlled trials to clarify their roles in clinical practice.
In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.
Yanık T, Yanık B. · Turkish journal of physical medicine and rehabilitation (2024)
What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke.
Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety.
In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics recently in the light of the current literature.
Accordingly, adjuvant treatment with neuroprotective substances appears to be a promising option, although more randomized prospective studies are still needed.
Grgac I, Herzer G, Voelckel WG, Secades JJ, Trimmel H. · Wiener klinische Wochenschrift (2024)
Some medications appear to be beneficial: N‑methyl-D-aspartate receptor (NMDA) antagonists (esketamine, amantadine, Mg++) reduce excitotoxicity and statins and cerebrolysin are known to counteract neuroinflammation.
By supporting the impaired mitochondrial energy supply, oxidative processes are inhibited and neuroregenerative processes, such as neurogenesis, angiogenesis and synaptogenesis are promoted by citicoline and cerebrolysin.
First clinical evidence shows an improvement in cognitive and thymopsychic outcomes, underlined by own clinical experience combining different therapeutic approaches.
These findings warrant further randomized trials to validate its efficacy and explore its long-term benefits.Registration: URL: https://www.clinicaltrials.gov ; unique identifier: NCT04904341.
Staszewski J, Dębiec A, Strilciuc S, Gniadek-Olejniczak K, Piusinska-Macoch R, Balo D, Harston G, Stępień A, Brzozowski K, Zięcina P, Narloch J, Wierzbicki M, Piasecki P. · Translational stroke research (2025)
Patients receiving Cerebrolysin achieved higher rates of mRS 0-2 at 90 days (68% vs. 44%, p = 0.016, OR 2.7, 95% CI 1.2-6.1; NNT: 4.2), had reduced risk of secondary ICH (14% vs. 40%, p = 0.02; RR 0.37, 95% CI 0.14-0.95), and had lower NIHSS on day 7 (median [IQR]: 3 [4] vs. 6 [9], p = 0.01).
There was a significant difference in Barthel Index scores between the Cerebrolysin group and the control group at 30 days (median [IQR]: 77 [32] vs. 63 [50], p = 0.03) and at 3 months (86 [22] vs. 75 [29], p = 0.01) primarily driven by the increase in the mobility and transfer components.
Multivariate analysis identified Cerebrolysin as an independent predictor of favorable outcomes at 3 months (OR 7.5, 95% CI 1.8-30.9), particularly in patients with diabetes (interaction OR 9.6, 95% CI 1.01-92).
A p < 0.05 was considered statistically significant.
Results: Stroke severity improved in both groups, but the adjuvant group demonstrated significantly greater reductions in NIHSS scores from 9.90 ± 2.90 to 3.40 ± 1.40 compared to the standard group, which improved from 10.10 ± 2.80 to 4.80 ± 1.30 ( t = 6.19, p < 0.001).
Additionally, 43.84% of patients in the adjuvant group shifted to minor stroke severity versus 25.71% in the standard group.
These findings support the potential cytoprotective effects of Cerebrolysin and highlight the utility of DTI and PCT for evaluating therapeutic efficacy and guiding individualized neuroprotective strategies.
Kalinin MN, Khasanova DR. · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2025)
The severity of ischemic injury and functional outcomes were largely influenced by the baseline condition of brain tissue and BBB integrity.
Conclusion Cerebrolysin treatment was associated with favorable changes in quantitative imaging biomarkers, indicating better preservation of brain microstructure, stabilization of BBB permeability, and a reduction in infarct volume in patients with AIS.
These findings support the potential cytoprotective effects of Cerebrolysin and highlight the utility of DTI and PCT for evaluating therapeutic efficacy and guiding individualized neuroprotective strategies.
Homberg V, Jianu DC, Stan A, Strilciuc Ș, Chelaru VF, Karliński M, Brainin M, Heiss WD, Muresanu DF, Enderby PM. · Stroke (2025)
The Cerebrolysin group also showed significant improvements (higher decreases) in National Institutes of Health Stroke Scale scores compared with the placebo group (2.085 [95% CI, 1.076-3.094] points; P <0.001).
Safety analysis raised no concerns (number of patients with adverse events P =0.105, number of adverse events per patient P =0.134).
Significant improvements were observed in language and neurological deficits, underscoring the importance of adjunctive therapies in nonfluent aphasia rehabilitation.